Current Headlines

  1. Clarivate Analytics Introduces Cortellis Content-As-A-Service (CaaS) To Accelerate Drug Discovery And Development

    Clarivate Analytics plc (NYSE:CCC; CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today launched an expansion to its Cortellis suite of life science intelligence solutions with programmatic access to scientific data typically used in drug discovery and early stage development

  2. Targeted Protein Degradation For Drug Discovery

    AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs)

  3. InSphero Launches Industry's First Automation-Compatible 3D Human Liver Disease Platform For NASH Drug Discovery And Screening

    InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

  4. Gotham Therapeutics And Mercachem Announce Progress In Compound Library Development Tailored For Epitranscriptomic Drug Discovery

    Gotham Therapeutics , a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and Mercachem, the leading European contract research organization, recently announced the generation of a high-quality compound library tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space

  5. Seelos Therapeutics Announces Investigational New Drug Application Submission For SLS-005

    Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase IIb/III clinical study of SLS-005 (trehalose) for the treatment of Sanfilippo syndrome (SFS)

  6. Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-ANG3

    Arrowhead Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH)

  7. Sosei Heptares Enters Into Multi-Target Research Collaboration And License Agreement With Genentech

    Sosei Group Corporation ("the Company") (TSE: 4565) announces that it has entered into a multi-target research collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop novel medicines (new small molecules and/or biologics) that modulate G protein-coupled receptor (GPCR) targets of interest to Genentech

  8. Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

    Gilead Sciences, Inc. and Galapagos NV recently announced that they have entered into a 10-year global research and development collaboration. 

  9. HOOKIPA Announces FDA Clearance Of IND Application For HB-201 Clinical Trial To Treat HPV-Positive Cancers

    HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial of HB-201, a TheraT®*-based immunotherapy, for the treatment of Human Papilloma Virus (HPV)-positive cancers is now effective following the clearance by the U.S. Food and Drug Administration (FDA)

  10. Pairing Targeted Drugs For Breast And Lung Cancer Could Overcome Treatment Resistance

    Scientists discovered that when the breast cancer drug palbociclib was combined with the lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own